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Theneuregulins (NRGs) play important roles in animal devel-
opment and homeostasis, and their deregulation has been
linked to diseases such as cancer and schizophrenia. The NRGs
belong to the epidermal growth factor (EGF) family of trans-
membrane growth factors. Although NRGs may be synthesized
as transmembrane proteins (the pro-NRGs), some of them lack
anN-terminal signal sequence, raising the questionof how these
pro-NRGs are directed to the plasma membrane. Here we have
explored the domains of pro-NRGs that are required for their
membrane anchoring, cell surface exposure, and biological
activity. We show that an internal hydrophobic region acts as a
membrane-anchoring domain, but other regions of pro-NRG
are required for proper sorting to the plasma membrane. Using
mutants that are located in different subcellular compartments,
we show that only plasma membrane-exposed pro-NRG is bio-
logically active. At this location, the pro-NRGs may act as
transautocrine molecules (i.e. as membrane factors able to acti-
vate receptors present in cells that are in physical contact with
the pro-NRG-producing cells (in trans) or capable of activating
receptors present in the pro-NRG-producing cells (in cis)).
The neuregulins (NRGs)6 are a group of polypeptide growth
factors that play critical roles in development (1, 2). Animals
lacking NRGs die in utero due to heart dysgenesis (3). In addi-
tion, a role of NRGs in the control of peripheral nervous system
homeostasis has also been demonstrated (4–6). Besides these
roles in animal development, deregulation of NRGs has been
linked to common diseases, such as cancer (7, 8) and schizo-
phrenia (5).With respect to the former, preclinical studies have
shown that expression of NRGs facilitates breast cancer cell
proliferation (9), migration, or invasiveness (10, 11), and tar-
geted expression of NRGs in the mammary gland of mice
results in the appearance of adenocarcinomas (12). Moreover,
increased expression of NRGs has been reported in different
types of solid tumors (7), and their presence correlates with the
response to some treatments used in the oncology clinic to
manage breast cancer (13).
Four NRG genes have been reported (NRG1 to -4), and
including all of the different splice variants and NRG isoforms,
30 different NRG isoforms have been described (1, 7). Accord-
ing to the structural components of their N-terminal region,
NRG1 gene isoforms are divided into three different types.
NRG1 type I isoforms (also termed heregulin, Neu differentia-
tion factor, or acetylcholine receptor-inducing activity (ARIA))
contain an Ig-like region, followed by a glycosylation-rich seg-
ment. The type II isoforms (also known as glial growth factors)
lack the glycosylation region while preserving the Ig-like mod-
ule. Finally, the type III isoforms (sensory and motor-derived
factor) lack both domains, which are substituted by a cysteine-
rich region. These domains are followed by an EGF-like mod-
ule, which catalogues the NRGs as part of the EGF family of
growth factors (14). This module is exposed to the extracellular
milieu in all pro-NRGs except in the case of pro-NRG3, which
is an intracellular pro-NRG isoform (15). The EGF-like module
is followed by a region of substantial variability, termed the
linker, that is critical for release of pro-NRGs to the extracellu-
lar medium (15–18). The linker of NRGs is followed by a short
hydrophobic region, which may act as a membrane anchor and
delimitates the extracellular from the intracellular C-terminal
domain. According to the length of the C-terminal domain,
three subtypes of NRGs have been described: a, b, and c (1).
Most NRGs are biosynthesized as membrane-anchored pre-
cursors. These precursor forms are cotranslationally inserted in
the membrane of the endoplasmic reticulum and are sorted to
the plasma membrane after trafficking through intracellular
compartments. Once at the plasmamembrane, pro-NRGsmay
reside at this cellular site, or they may be cleaved to be released
as soluble factors by the action of cell surface metalloproteases
of the ADAM family (18). Although these biosynthetic and
functional properties are shared by other membrane-anchored
growth factors, the fact that type I pro-NRGs lack an N-termi-
nal signal sequence (15, 19–22) raises the question of how these
pro-NRGs are targeted to the plasmamembrane. This question
is especially relevant because theN terminus of other EGF fam-
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ily growth factors is expected to direct them to the cell surface.
Thus, in the case of proamphiregulin, removal of its N-terminal
region, which includes the N-terminal hydrophobic signal
sequence, prevents its correct transport to the plasma mem-
brane (23). The intracellular distribution of pro-NRG3, an iso-
form that lacks the internal hydrophobic and C-terminal
domains, suggested that these regions could be involved in ade-
quate cell surface sorting of NRGs (15). However, deletion of
the linker region of pro-NRG2c provokes its intracellular
retention, indicating that other regions of pro-NRGs may also
participate in the sorting of pro-NRGs to the plasmamembrane
(17).
Cell surface membrane-bound pro-NRGs retain biological
activity, indicating that cleavage of the transmembrane protein
may not be critical for its activity (9, 17, 24). This conclusion is
based on experimental systems inwhich uncleavable pro-NRGs
have been demonstrated to activate the NRG receptors (the
ErbB/HER family of receptors) on adjacent cells (in trans or
juxtacrine) (17, 24). However, whether pro-NRGs may activate
ErbB receptors present in the same cell that produces the trans-
membrane NRG (in cis or autocrine) is not known. Some prec-
edents of this kind of interaction have been reported in the case
of the related family member pro-EGF. Thus, intracellular
entrapment of pro-EGF has been reported to activate the EGF
receptor (25, 26). This property, termed intracrine stimulation,
may promote migration of mammary epithelial cells (27). It is
therefore possible that pro-NRGs, which are expected to travel
to the cell surface crossing the same intracellular compart-
ments as the cognate receptors, may behave analogously.
In this paper, we have performedmolecular as well as biolog-
ical analyses to define the domains of pro-NRGs required for
their adequate cell surface exposure and biological actions. In
addition, we investigated whether membrane-anchored pro-
NRGs are functional while traveling along their biosynthetic
route. Finally, we also explored whether pro-NRGs can activate
their receptors in cis.
EXPERIMENTAL PROCEDURES
Reagents and Immunochemicals—Culture media, sera, and
G418 were purchased from Invitrogen (Carlsbad, CA). Protein
A-Sepharose was from Amersham Biosciences. Immobilon-P
membranes were from Millipore Corp. (Bedford, MA). DAPI,
brefeldin A, proteinase K, protein A-HRP, and doxycycline
were from Sigma. TAPI-2 was from Calbiochem. Wheat germ
agglutinin-agarose was from GE Healthcare. Other generic
chemicals were purchased from Sigma, Roche Applied Science,
or Merck.
The anti-NRG endodomain antibody was raised against the
sequence NH2-CETPDSYRSDPHSER-COOH, which corre-
sponds to the C-terminal residues of rat NRG2c (18). For the
generation of the anti-NRG ectodomain antibody, rabbits were
immunized with a GST fusion protein that included amino
acids 19–181 of rat NRG2c (17). The anti-phospho-Akt anti-
body was raised in our laboratory and recognizes the sequence
NH2-CRPHFPQFpSYSAS-COOH. Anti-Akt, anti-phospho-
Erk1/2, anti-Erk2, anti-GAPDH, anti-ErbB3, anti-ErbB4, and
anti-phosphotyrosine antibodies were from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA). The anti-Erk5 antibody was
generated in our laboratory (28). The Ab3 antibody used to
detect ErbB2 in Western blots was from Calbiochem-Merck.
The monoclonal antibody anti-ErbB2 ectodomain as well as
recombinant NRG were generously provided by Dr. Mark X.
Sliwkowsky (Genentech, San Francisco, CA). The anti-pErbB2
antibody was from Cell Signaling (Cambridge, MA). The
anti-HA antibody was from Roche Applied Science. Trastu-
zumab was obtained from a local pharmacy. Antibodies against
calnexin and protein-disulfide isomerase (PDI) were obtained
from Stressgen (San Diego, CA). Antibodies to GM130 and
p230 were from BD Transduction Laboratories (Lexington,
KY). The Cy3- or Cy2-conjugated antibodies were purchased
from Jackson Immunoresearch (West Grove, PA), and Alexa
488-conjugated antibodies were from Invitrogen. HRP conju-
gates of anti-rabbit or anti-mouse IgG were from Bio-Rad. The
Alexa 546 kit used for the labeling of anti-ErbB3 and -pErbB2
antibodies was from Invitrogen. The anti-pErbB2 antibody was
raised against the sequence NH2-CSPQPEpYVNQPD-COOH
of human ErbB2 phosphorylated at tyrosine 1139. For the gen-
eration of the anti-ErbB3 antibody, rabbits were immunized
with aGST fusion protein that included 166 intracellular amino
acids of human ErbB3.
Cell Culture and Transfections—The conditions for the cul-
ture ofMCF7 and 293 cells have been described previously (17).
Transfections in 293 orMCF7 cells were performed by calcium
phosphate (29) or using Lipofectamine (Invitrogen), respec-
tively. Clones were selected by G418 resistance, and their NRG
expression was analyzed by Western blotting. The MCF7-
NRG2ctetoff clone has been described previously (9).
Plasmids—The plasmid containing thewhole sequence of rat
pro-NRG2c (pcDNA3-NRG2c) was generated by double
digestion with KpnI and NotI restriction enzymes. NRG2cIg
mutant was generated by digesting the pcDNA3-NRG2c con-
struct with BamHI because the immunoglobulin domain is sur-
rounded by sites for this enzyme. Other mutants were gener-
ated by PCR using the following primers: NRGintra (forward,
5-AAGCTTATGTCTGAGCGCAAAGAAGG-3; reverse,
5-G CCGATCAAGCTTTTACCGCTGCTTCTTGG-3),
NRGextra (forward, 5-AG GAA TCC GTG CTG ACA ATT
ACT G-3; reverse, 5-TAT TCT AGA TTA CCT TTC GCT
ATGAGG-3), NRG3-like (forward, 5-AAGCTTATGTCT
GAG CGC AAA GAA GG-3; reverse, 5-CC AAG CTT TTA
GTA GAG TTC CTC CGC TTT TTC-3). PCR products were
digested with HindIII, EcoRI, or XbaI and subcloned in the
pcDNA3 vector (Invitrogen). To obtain clones of the mutants
that can be reprimed, sequences were subcloned in the
pRevTRE vector (BD Biosciences) after PCR amplification and
SalI combined with ClaI (NRG3-like) or HindIII (NRGintra)
digestion. The NRG2c-GFP fusion protein was generated by
PCR using the following primers: forward, 5-ACC CTC GAG
ATG TCT GAG CGC AAA GAA GGC-3; reverse, 5-TTT
GAA TTC GCC CTT TCG CTA TGA GGA GA-3. The PCR
productwas digestedwithXhoI andEcoRI and subcloned in the
plasmid pEGFP-N3 (BD Biosciences).
Chimeras of HA-ERK5 with different regions of pro-
NRG2c were constructed as follows. The HA-ERK5 full-
length cDNA was amplified using the primers 5-AAG CTT
ATG TAC GAC GTT CCT GAT-3 (forward) and 5-CTC
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GAG GGG GTC CTG GAG GTC-3 (reverse), digested with
HindIII and XhoI, and subcloned into pCDNA3. For the con-
struction of HA-ERK5-NRG2c, the stop codon of ERK5 was
eliminated to allow in frame continuation of protein synthesis
of the transmembrane and intracellular regions of pro-
NRG2c. These regions of pro-NRG2c, corresponding to
amino acids 231–422, were PCR-amplified with the primers
5-CTC GAG ACC CAA GAA AAA GCG-3 (forward) and
5-TCTAGATTACCTTTCGCTATGAGG-3 (reverse) and
fused to the C terminus of HA-ERK5. To create the chimera
containing the ectodomain plus transmembrane region of pro-
NRG2c, the region coding for amino acids 1–273 was PCR-
amplified using the primers 5-AAG CTT ATG TCT GAG
CGCAAAGAAGG-3 (forward) and 5-TCTAGATTACCT
TTCGCTATGAGG-3 (reverse) and fused to the N terminus
of HA-ERK5 (forward, 5-AAG CTT ATG TAC GAC GTT
CCT GAT-3; reverse, 5-TCT AGA TCA GGG GTC CTG
GAG GTC-3). Construction of the HA-ERK5-TM2c was
prepared by PCR-amplifying amino acids 231–267 of pro-
NRG2c using the primers 5-CTCGAGACCCAAGAAAAA
GCG-3 (forward) and 5-TCT AGA TTA CTG CCG CTG
CTT CTT GGT-3 (reverse), and the resulting fragment was
fused to the C terminus of HA-ERK5 (forward, 5-AAG CTT
ATG TAC GAC GTT CCT GAT-3; reverse, 5-CTC GAG
GGG GTC CTG GAG GTC-3).
Metabolic Labeling—MCF7-NRG2c or MCF7-NRGintra
cells were plated in 100-mm dishes and grown to 80% conflu-
ence. Cells were washed twice for 20 min each with methio-
nine- and cysteine-free DMEM and then were incubated in the
same medium containing 200 Ci/ml of a mixture of [35S]me-
thionine and [35S]cysteine (EasyTagTM Express35S protein
labeling mix, PerkinElmer Life Sciences) for 20min. The radio-
active medium was replaced with fresh complete medium, and
cells were chased for the indicated times. Cells were lysed, and
then lysates were precleared by the addition of 50 l of protein
A-Sepharose. After incubation at 4 °C for 30 min in a rocking
platform, the lysates were centrifuged at 10,000 g for 10 s, and
the supernatants were transferred to new tubes containing the
antibodies (anti-endodomain antibody to precipitate pro-
NRG2c or anti-NRG to precipitate NRGintra). Lysates were
incubated for 2 h at 4 °C, and then 50l of protein A-Sepharose
were added for an additional 30 min. The precipitates were
washed five times with radioimmune precipitation buffer and
boiled in electrophoresis sample buffer. Samples were run in
8% (for pro-NRG2c) or 10% (for NRGintra) SDS-polyacryl-
amide gels that were fixed and dried before exposure to auto-
radiographic film or PhosphorImager screens for quantita-
tive analyses.
Immunoprecipitation and Western Blotting—Cells were
washed with PBS and lysed in ice-cold lysis buffer (140 mM
NaCl, 10mMEDTA, 10% glycerol, 1%Nonidet P-40, 20mMTris
(pH 7.0), 1 M pepstatin; 1 g/ml aprotinin, 1 g/ml leupeptin,
1 mM PMSF, and 1 mM sodium orthovanadate). After scraping
the cells from the dishes, samples were centrifuged at 10,000 
g at 4 °C for 10 min, and supernatants were transferred to new
tubes. Immunoprecipitations were performed with the corre-
sponding antibody and protein A-Sepharose at 4 °C for at least
2 h, and the immune complexes were recovered by a short cen-
trifugation followed by three washes with 1 ml of cold lysis
buffer. Samples were then boiled in electrophoresis sample
buffer and loaded in SDS-polyacrylamide gels. After transfer to
PVDF membranes, these were blocked for 1 h in Tris-buffered
saline with tween containing 1% BSA and then incubated for
2–16 h with the corresponding antibody. After washing with
Tris-buffered saline with tween, membranes were incubated
with HRP-conjugated secondary antibodies for 30 min and
washed, and bands were visualized by a luminol-based system
with p-iodophenol enhancement (30).
Subcellular Fractionation—Cell fractionation experiments
were performed as described previously (31). Cells grown in
100-mmdishes until 90% of confluencewerewashed twicewith
PBS and incubated for 10minwith 0.25 M sucrose, 1mMEDTA,
1 mM PMSF, and 10mMTris, (pH 7.0). The cell suspension was
homogenized on ice with a tightly fitting Dounce homogenizer
(50 strokes) and centrifuged at 4,000 g for 10min. The result-
ing pellet was rehomogenized and centrifuged at the same
speed. The supernatants from these centrifugation steps were
pooled and centrifuged at 30,000  g for 30 min. The superna-
tant was considered the cytosolic fraction, and the pellet was
considered the microsomal fraction.
Immunofluorescence and FRET Experiments—Cells cultured
on glass coverslips were washed with PBS and fixed in 2%
p-formaldehyde for 30 min at room temperature, followed by
two rinses in PBS. Monolayers were then permeabilized three
times for 10 min each with PBS supplemented with 0.1% (final
concentration) Triton X-100 and then blocked twice in PBS
with 0.2% BSA for 10min each at room temperature. Cells were
incubated with the indicated primary antibodies in blocking
solution for 2 h at room temperature or overnight at 4 °C. After
three washes for 10 min each in PBS with 0.2% BSA, coverslips
were incubated with Cy3- or Alexa 488-conjugated secondary
antibodies for 30 min and washed three times in PBS with
0.2% BSA. Immunolabeled cells were counterstained with
DAPI to detect cell nuclei, and then the slides were mounted.
Samples were analyzed by regular epifluorescence micros-
copy or by confocal immunofluorescence microscopy using
a Zeiss LSM510 system. To avoid interference between
fluorescence signals, confocal images were captured under
multitracking mode.
MCF7 cells expressingNRG-GFPwere cultured on glass cov-
erslips. EGFP fluorescence was excited with the argon 476-nm
laser line and detected between 487 and 540 nm, whereas Alexa
546 was excited at 561 nm and detected between 571 and 680
nm. To minimize cross-talk between the channels, each image
was collected separately in the multitrack mode. Acceptor
photobleaching was achieved by scanning 20 times a region of
interest using the 561-nm laser line at 100% intensity. To min-
imize the effect of photobleaching of the donor during the
imaging process, the image acquisition was performed at low
intensities. FRET efficiencywasmeasured after photobleaching
of the Alexa 546 fluorochrome bound to anti-pErbB2 or anti-
ErbB3 antibody, using the software Leica LAS AF (Leica). The
results are plotted as the mean  S.D. of arbitrary units
obtained in three different experiments in which at least 10
distinct areas per experiment and condition were analyzed.
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Analysis of Cell Surface Pro-NRG—Cell surface expression of
NRG mutants was determined by FACS using the anti-NRG
ectodomain antibody. Cells were washed twice with PBS,
scraped, and collected into 15-ml tubes. Then they were
washed again with PBS and resuspended in 1 ml of PBS con-
taining 2% BSA and 2 l of the anti-NRG antibody. After 1 h
of incubation at room temperature, cells were washed twice
and resuspended in PBS/BSA containing the secondary anti-
rabbit IgG antibody conjugated to FITC. After a 30-min
incubation, the cells were washed with PBS. Finally, the
mean light intensity was measured using the CellQuest
application in a FACSCalibur cytometer (BD Biosciences).
MTT Metabolization Assays—Subconfluent monolayer cul-
tures were trypsinized, and cells were plated in 24-well plates to
a density of 20,000 cells/well and cultured overnight in DMEM
plus 10% FBS. The next day, the medium was replaced with
DMEM without FBS, with or without the indicated treatment.
Cell proliferation was analyzed at 3 days by an MTT-based
assay as described (9). The results are presented as the mean 
S.D. of quadruplicates of a representative experiment that was
repeated at least three times.
Statistics and Quantitative Estimation of Pro-NRG Forms—
Results obtained in the proliferation experiments are repre-
sented as the mean  S.D. of at least three independent exper-
iments. Significance was considered when p values were0.05.
Quantitation of the different pro-NRG forms in gels from
radioactive pulse-chase experiments was performed using the
Quantity One software version 4.1.1 (Bio-Rad). Quantitation of
the autoradiographic bands obtained fromWestern blot exper-
iments was performed using the ImageJ version 1.44 software
(National Institutes of Health, Bethesda, MD). The intensity of
each of the different bands was calculated, and the sum of all in
each lane was obtained. Data are represented as the percentage
of the maximum value obtained for each experiment.
RESULTS
Plasma Membrane Sorting of Pro-NRG2c Mutants—Using
pro-NRG2c as a model for the study of type I transmembrane
NRGs, we formerly reported that a small region in the extracel-
lular juxtamembrane domain controlled its sorting to the
plasma membrane (17). To identify additional domains that
may also participate in membrane sorting and/or membrane
anchoring of pro-NRG2c, we used a strategy based on the
creation of various deletion mutants that eliminated different
regions of the intracellular or extracellular domains (Fig. 1A).
Mutants of the ectodomain included the pro-NRGIg, in which
the Ig-like domain has been deleted, and the pro-NRGextra
form, in which the extracellular domain has been removed. The
pro-NRGintra form was created by removing the intracellular
domain of pro-NRG2c. The pro-NRG3-like form was cre-
FIGURE 1. Expression and analyses of cell surface exposure of different pro-NRG2c forms. A, schematic representation the different mutants of pro-
NRG2c, also indicating the number of amino acids of each construction and regions recognized by the two different anti-NRG antibodies used. B, expression
of the different mutants in 293 cells. 293 cells transfected with the cDNA coding for the different mutants were lysed, and cell extracts were immunoprecipi-
tated (IP) with the anti-NRG or anti-endodomain antibodies. The samples were run on SDS-polyacrylamide gels that were transferred to PVDF membranes. The
blots were probed with the same antibodies used to immunoprecipitate the samples. The position of the Mr markers is shown at the right. C, protease
protection experiments. Intact 293 cells expressing the different mutants were treated with or without proteinase K (PK; 200 g/ml) for 30 min and lysed. The
samples were analyzed by Western blot with the anti-endodomain or anti-NRG antibodies. D, FACS analyses of NRG cell surface exposure. Cells were incubated
with the anti-NRG antibody followed by an anti-rabbit antibody conjugated to FITC. Fluorescence intensity was measured with a FACSCalibur Flow cytometer.
Filled histograms correspond to signals from cells incubated with the secondary antibody alone, whereas gray line histograms represent the fluorescence due
to the expression of different NRG forms. aa, amino acids.
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ated by a stop codon that interrupted reading of pro-NRG2c
right before the internal hydrophobic region, to mimic pro-
NRG3 (1). cDNAs coding for these different deletionmutants
were transfected into 293 cells, and expression was assessed
with antibodies that detect either the ectodomain or the intra-
cellular C terminus of pro-NRG2c. As shown in Fig. 1B,West-
ern blotting with the anti-ectodomain antibody recognized all
of the mutants, except the pro-NRGextra form. As expected,
the latter was, however, recognized by the anti-endodomain
antibody, which also recognized wild type pro-NRG2c or the
pro-NRGIg mutant. Pro-NRG3-like as well as the pro-
NRGintra forms were only recognized by the anti-ectodomain
antibody. Both the anti-ectodomain and anti-endodomain
antibodies recognized several bands that correspond to distinct
molecular forms. In fact, in the case of the wild type pro-
NRG2c form, former studies indicated that its expression in
293 cells resulted in the presence of a slower migrating band
that corresponds to mature pro-NRG2c (Fig. 1C) (17, 18)
together with two other immature, intracellular bands that
migrate faster. In addition, we frequently detect another pro-
NRG2c form that corresponds to a truncated version. Finally,
a group of smallerMr bands solely detected by the anti-endodo-
main antibody are also present and are generated by cleavage of
the ectodomain of pro-NRG2c. These forms correspond to
cell-associated tail fragments devoid of the NRG-EGF-like
domain (18).
Proteinase K treatment of intact pro-NRG2c-expressing
cells has been used to determine plasmamembrane exposure of
this progrowth factor (17, 18). In fact, treatment with protein-
ase K strongly decreased the amounts of the mature and the
truncated forms, indicating that they were exposed at the cell
surface (Fig. 1C). In contrast, the amount of the lowerMr imma-
ture forms remained unchanged upon treatment with the pro-
tease, confirming that these forms are intracellular and are
therefore protected from the action of the protease. Treatment
of cells expressing the pro-NRGIg mutant yielded analogous
results; the slowest migrating band was sensitive to treatment
with proteinase K, whereas the slightly faster migrating forms
were insensitive. In 293 cells expressing either the wild type
pro-NRG2c or the pro-NRGIg mutant, treatment with pro-
tease K resulted in an increase in the amount of the cell-associ-
ated tail fragments. ProteaseK treatment of 293 cells expressing
the pro-NRGintra, the pro-NRGextra, or the pro-NRG3-like
forms did not cause a detectable effect on the amount of any of
the forms expressed.
We further inspected plasmamembrane exposure of the dis-
tinct mutants by flow cytometry using the anti-ectodomain
antibody. As shown in Fig. 1D, staining indicative of cell surface
exposure was observed for wild type pro-NRG2c or the pro-
NRGIg mutant but not in the case of pro-NRGintra or the
pro-NRG3-like forms. The pro-NRGextra form, because it
lacks the extracellular domain, could not be detected by the
antiectodomain antibody, and therefore this technique could
not be used to define whether this form reached the plasma
membrane. Taken together, these data indicated that pro-
NRG2c or pro-NRGIg was targeted to the plasmamembrane,
but pro-NRGintra and the pro-NRG3-like forms failed to
reach this location.
Membrane-anchoring Properties of Pro-NRG2c Mutants—
Toanalyze themembrane-anchoring properties of the different
pro-NRG2c mutants, we performed a simple subcellular frac-
tionation procedure to segregate the light (cytosolic fraction)
from the heavy (microsomal) fractions. The nuclear compart-
ment was not isolated for analysis in these experiments. Wild
type pro-NRG2c, pro-NRGIg, pro-NRGextra, and pro-
NRGintra associatedwith the heavy fraction (Fig. 2A). The pro-
NRG3-like form was present in the cytosolic fraction but not
in microsomes, indicating that this form, in contrast to the
other mutants tested, was unable to tightly associate to cellular
membranes. Western blotting of samples from each fraction
with markers of cytosol (GAPDH) or microsomes (calnexin)
confirmed the separation between both fractions.
The above data indicated that the internal hydrophobic
region of pro-NRG2c was required and sufficient for mem-
brane anchoring. We next asked whether that region had suffi-
cient strength to target a protein to the plasma membrane or
could confer membrane-anchoring properties to a cytosolic
protein. To address this, we created several chimeras of pro-
NRG2c and ERK5 (schematically represented in Fig. 2B).
ERK5 is a member of the MAPK family of signal transducers
and mainly locates in the cytosolic compartment (32). One of
the chimeras included the ectodomain and the transmembrane
region of pro-NRG2c (residues 1–273) fused to HA-ERK5
(NRG2c-ERK5). A second chimera, which was named ERK5-
NRG2c, included HA-ERK5 fused to the transmembrane and
intracellular regions of pro-NRG2c (residues 231–422).
Finally, a third chimera (ERK5-TM2c) consisted of ERK5
fused to the minimal internal hydrophobic region of pro-
NRG2c (residues 231–267). 293 cells were transfected with
the cDNAs coding for these different mutants, and their
expression was analyzed by Western blotting using anti-HA to
differentiate endogenous from exogenous ERK5 or using anti-
ERK5 to detect endogenous ERK5 that we used as a control for
the cytosolic fraction. The distinct Mr between endogenous
ERK5 and the chimeras allowed us to use it for that purpose.
Cell fractionation experiments indicated that ERK5-NRG2c,
NRG2c-ERK5, and ERK5-TM2c associated with the micro-
somal fraction, whereas endogenous ERK5 was mainly cytoso-
lic (Fig. 2C). We also explored whether the chimeras reached
the plasma membrane. Proteinase K protection experiments
indicated that none of these three chimeras was able to be
exposed at the plasma membrane because they offered resist-
ance to treatmentwith the protease (Fig. 2D).Moreover, immu-
nofluorescence experiments with an anti-HA antibody showed
intracellular staining of all of these chimeric proteins (Fig. 2E).
Together, these data supported the concept that the internal
hydrophobic region of pro-NRG2c is strong enough to drive
membrane association of a protein but is unable to force the
expression of any protein at the plasma membrane.
Subcellular Location of the Pro-NRG2c Mutants—We pro-
ceeded to explore the subcellular location of the different
mutants by immunofluorescence microscopy. These analyses
confirmed previously published data on the subcellular distri-
bution of pro-NRG2c, which was located at the plasma mem-
brane and the Golgi apparatus because it colocalized with the
Golgi marker GM130 (17) (Fig. 3A). The distribution obtained
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with the pro-NRGIgmutant was very similar to that of thewild
type protein. Staining of 293 cells expressing the pro-NRGextra
form revealed a pattern consistent with this mutant being
located at the plasma membrane (Fig. 3A). Previously, it has
been proposed that pro-NRG3 was a nuclear protein (15). In
line with this, the immunofluorescence data indicated that
this form was located in a region that corresponded to the
nuclear compartment because it colocalized with DAPI
staining (Fig. 3B).
Pro-NRGintra colocalized with Golgi markers (GM130 and
p230), and also some colocalization was observed with the ER
marker PDI (Fig. 3C). No clear plasma membrane location was
observed. Although the pro-NRGintra was associated with the
microsomal fraction, its failure to move to the plasma mem-
brane could be affected by defective entry into the lumen of the
ER (e.g. by failure to translocate the N terminus to the lumen,
therefore leaving that region exposed to the cytosolic compart-
ment). To investigate this, we took into consideration the fact
that entry of pro-NRG2c into the ER luminal compartment is
accompanied by glycosylation (17). To follow this posttransla-
tional modification, we performed wheat germ agglutinin pre-
cipitation of the pro-NRGintra form and compared it with wild
type pro-NRG2c, pro-NRGextra, and the pro-NRG3-like
form. The latter two formswere used as controls because one of
them (pro-NRGextra) lacks the ectodomain, and the other is
not membrane-associated (pro-NRG3-like). Wheat germ
agglutinin efficiently precipitated wild type pro-NRG2c as
well as pro-NRGintramutant (Fig. 3D). In contrast, wheat germ
agglutinin failed to precipitate the pro-NRG3-like and pro-
NRGextra forms.
Biological Properties of the Different Pro-NRG2c Mutants—
Because previous reports on mutant pro-EGF forms indicated
that intracellularly trapped pro-EGFwas biologically active (25,
27), we decided to explore whether intracellular pro-NRG
behaved analogously. In addition, we also attempted to eluci-
date whether pro-NRG3 was active in terms of proliferation.
Previously, we established a system for the evaluation of the
biological properties of membrane-anchored pro-NRGs,
using MCF7 cells as a reporter cell line (9). This cell line
expresses levels of ErbB/HER receptors that are analogous to
those present in the normal breast epithelium (33) and
responds mitogenically to soluble NRG (34). Furthermore,
expression of wild type pro-NRG2c in these cells strongly
stimulates their proliferation (9). We therefore created
FIGURE 2. The internal hydrophobic region of pro-NRG2c is responsible for its membrane anchoring. A, cell fractionation experiments of the different
mutants of pro-NRG2c. Cells expressing the different forms were fractionated as described under “Experimental Procedures,” and cytosolic or microsomal
fractions were analyzed for pro-NRG, GAPDH, and calnexin by Western blot. The position of the Mr markers is shown at the right. B, schematic representation
of ERK5-NRG2c, NRG2c-ERK5, and ERK5-TM2c chimeras. C, the cytosolic (C) and microsomal (M) compartments of 293 cells transfected with the cDNA
coding for the different chimeras were analyzed for pro-NRG2c and ERK5 by Western blot. D, 293 cells expressing the different chimeras were treated with
proteinase K (PK). The cell extracts were immunoprecipitated with the anti-HA antibody, and the Western blots were analyzed with the same antibody.
E, immunofluorescence analysis of the subcellular distribution of the chimeric proteins in 293 cells, in which these proteins were stained with the anti-HA
antibody.
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MCF7 derivatives from the parental cell line MCF7tetoff, in
which expression of the different pro-NRG forms to be ana-
lyzed (pro-NRG2c, pro-NRGintra, and pro-NRG3-like)
could be regulated by the addition of the tetracycline analog
doxycycline. This strategy was chosen to avoid clonal differ-
ences between the distinct transfectants. We did not con-
template further analysis of pro-NRGIg mutant because in
previous cell biological experiments it behaved as the pro-
NRG2c wild type protein. Expression of the different forms
in distinct clones and their repression by doxycycline were
assessed byWestern blotting with the anti-ectodomain anti-
body, and clones with analogous levels were selected for fur-
ther studies (Fig. 4A). Two different clones of each cell line
were used, although the data described below correspond to
a representative one.
Immunofluorescence studies revealed that the subcellular
location of these mutants in MCF7 cells offered a distribution
analogous to that observed in 293 cells (Fig. 4B). To analyze the
proliferation properties of MCF7 cells expressing the different
pro-NRG forms,we performedMTTmetabolization studies. In
these experiments, we used exogenousNRG as a control for the
maximum growth factor-induced proliferation. MCF7tetoff
cells, which represented the parental cell line from which
clones of the different pro-NRG forms were obtained, had low
proliferation in serum-free conditions, and this proliferation
was unaffected by the addition of doxycycline (Fig. 4C). The
addition ofNRG resulted in a strong proliferation response that
was also unaffected by the addition of doxycycline. MCF7-
NRG2c cells efficiently proliferated in serum-depleted culture
medium, and the proliferation was strongly inhibited by the
addition of doxycycline. The amount of proliferation obtained
with the expression of wild type pro-NRG2c was analogous to
that obtained by supplementing the culturemediumwith exog-
enous soluble NRG. The action of the latter was similar in cells
treated with doxycycline, indicating that this compound did
not affect the response of the cells to NRG and suggesting that
the decrease in proliferation in the presence of doxycycline is in
fact due to repression of pro-NRG2c synthesis. In contrast to
MCF7-NRG2c cells, MCF7 cells expressing pro-NRGintra or
pro-NRG3-like forms had very low proliferation, analogous to
that of wild type untransfected MCF7 cells. Moreover, MCF7-
NRGintra and MCF7-NRG3-like cells failed to proliferate
when expression of the two mutant forms was allowed. How-
ever, stimulation of these cell lines with exogenous NRG
increased their MTT metabolization to levels analogous to
those observed in untreated or NRG-treated MCF7-NRG2c
FIGURE 3. Subcellular localization of pro-NRG2c mutants. Distribution of pro-NRG2c, pro-NRGIg, and pro-NRGextra (A) and NRG3-like (B) in 293 cells
was assessed by immunofluorescence using the anti-NRG or anti-endodomain antibodies as described under “Experimental Procedures.” Golgi apparatus
localization was determined by immunofluorescence using an anti-GM130 antibody, and nuclear staining was performed with DAPI. C, detection of the
pro-NRGintra mutant in 293 cells by immunofluorescence with the anti-endodomain antibody. Colocalization with the cis-Golgi was determined using
anti-GM130 antibody, and colocalization with the trans-Golgi apparatus was determined with the anti-P230 antibody. The endoplasmic reticulum was stained
with the anti-protein-disulfide isomerase (PDI) antibody. D, glycosylation of different pro-NRG2c mutants. Protein extracts of 293 cells expressing each
construct were precipitated with wheat germ agglutinin-agarose (WGA) for 2 h and centrifuged, and complexes were resolved in a 10% SDS-polyacrylamide
gels. Detection of pro-NRG forms was carried out by Western blot using the anti-ectodomain and anti-endodomain antibodies.
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cells, indicating that MCF7tetoff cells expressing those two
mutant forms retained the capability to mitogenically respond
to exogenously added NRG.
We also explored the proliferation of MCF7-NRGintra and
MCF7-NRG3-like cells in response to trastuzumab, a mono-
clonal antibody designed to the extracellular domain of HER2.
This antibody has formerly been shown to prevent proliferation
of MCF7-NRG2c cells because it uncouples pro-NRG2c-
ErbB receptor interaction (9). Treatment with this antibody
efficiently prevented proliferation of MCF7-NRG2c cells but
did not affect proliferation of MCF7-NRGintra and MCF7-
NRG3-like cells (Fig. 5A). Remarkably, the MTT metaboliza-
tion values reflecting inhibition of proliferation of MCF7-
NRG2c cells treated with trastuzumab reached values
analogous to those obtained in MCF7-NRGintra and MCF7-
NRG3-like cells.
To analyze whether these biological differences in terms of
cell proliferation also reflected differences in signaling, we
explored the activation state of HER receptors and intracellular
signaling pathways related to cell proliferation/survival in
MCF7 cells. ErbB2, ErbB3, and ErbB4were constitutively phos-
phorylated in tyrosine residues inMCF7-NRG2c cells but not
in the other cell lines (Fig. 5B). This level of phosphorylated
ErbB receptors was regulated by doxycycline, indicating that
such activation of ErbB receptor tyrosine phosphorylation
depended upon the expression of pro-NRG2c. In contrast, the
resting phosphorylation in tyrosine residues of these receptors
was very low in MCF7-NRGintra and MCF7-NRG3-like cells
and was insensitive to doxycycline. Analogously, resting phos-
pho-Akt phosphorylation at Ser473 and dual phosphorylation of
Erk1/2 were also detected in MCF7-NRG2c cells but not in
MCF7-NRGintra and MCF7-NRG3-like cell lines. However,
the latter two cell lines retained normal responsiveness to exog-
enous NRG, as indicated by the efficient level of tyrosine phos-
phorylation of the ErbB receptors and the phosphorylation of
Akt and Erk1/2 in response to exogenously added solubleNRG.
The failure of MCF7-NRGintra cells to proliferate raised the
question of whether this lack of activity could be due to insta-
bility of this mutant as compared with wild type pro-NRG2c.
To explore such a possibility, pulse-chase as well as doxycycline
repression experiments were performed. For the pulse-chase
experiments, MCF7 cells expressing pro-NRG2c or pro-
NRGintra were metabolically labeled with 35S-amino acids for
20min and then chased in normal culturemedium for different
FIGURE 3—continued
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times. As shown in Fig. 5C and in agreement with previously
published data (17), wild type pro-NRG2cwas initially synthe-
sized as two forms of 70 and 72 kDa, which were rapidly con-
verted into mature forms of higher Mr (80 kDa), whose
amount progressively decreased. Pro-NRGintra was synthe-
sized as a band of 44 kDa (Fig. 5C) whose amount also decreased
over time. Quantitative analyses indicated analogous half-lives
for pro-NRG2c andpro-NRGintra (Fig. 5D).We also explored
the half-lives of the two proteins upon repression of their
mRNAs by doxycycline in the MCF7tetoff cellular model. The
addition of doxycycline caused a progressive loss of both pro-
NRG2c and pro-NRGintra (Fig. 5E). The decrease in their
amount upon doxycycline-mediated repression followed a sim-
ilar time course, as indicated by quantitative analyses of the
blots (Fig. 5F). Together, the above data demonstrate that the
half-lives of both proteins were similar, indicating that the dif-
ferences in their biological properties could not be caused by
distinct stability properties of pro-NRGintra as compared with
wild type pro-NRG2c.
Pro-NRG2c May Act in Cis at the PlasmaMembrane—The
above results demonstrated that cell surface exposure of pro-
NRG2c was required for its action and indicated that intracel-
lularly trapped pro-NRGwas unable to activate its receptors. A
scenario that could explain this behavior could be that of pro-
NRG being only able to activate ErbB receptors on neighboring
cells (in trans) but not the self ErbB receptors (in cis). That
transmembrane pro-NRG is able to activate receptors in trans
has already been reported (17, 24). We therefore explored here
whether pro-NRG could also act in cis. For these experiments,
we employed several strategies. First, we used an intracellularly
GFP-tagged form of pro-NRG and analyzed whether such a
form was able to interact with ErbB3, which acts as its major
receptor in MCF7 cells, or activated ErbB2, which forms oligo-
meric complexes with ErbB3 upon binding of pro-NRG to
FIGURE 4. Biological activity of the different pro-NRG2c mutants. A, expression of the different mutants of pro-NRG2c in MCF7tetoff cells. Clones of
MCF7tetoff expressing the different mutants of pro-NRG2c (MCF7tetoff-NRG2c, MCF7tetoff-NRGintra, and MCF7tetoff-NRG3-like) were cultured with or without
doxycycline (DOX; 10 ng/ml) for 2 days and lysed. The samples were analyzed by Western blot with the anti-ectodomain antibody. B, subcellular distribution of
pro-NRG2c mutants in MCF7tetoff cells was analyzed by immunofluorescence using the anti-ectodomain antibody. ErbB2 receptor distribution was assessed
by immunofluorescence with the 4D5 antibody. C, proliferation of MCF7tetoff, MCF7tetoff-NRG2c, MCF7tetoff-NRGintra, and MCF7tetoff-NRG3-like cells. Cells
cultured in the presence or absence of doxycycline (10 ng/ml) were treated with or without NRG (10 nM), and MTT metabolization was measured 3 days later.
Results are presented as the mean  S.D. of quadruplicates of an experiment that was repeated twice.
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ErbB3 (schematically represented in Fig. 6A). Fluorescence
microscopy verified a correct membrane exposure of pro-
NRG-GFP, indicating that the addition of the extra GFP
sequence apparently did not affect expression of that protein to
the plasma membrane (Fig. 6B). Individualized MCF7 cells
expressing NRG-GFPwere analyzed for FRET using NRG-GFP
as a donor and Alexa 546-labeled anti-ErbB3 or anti-pErbB2 as
acceptors. FRET measurements indicated transfer of energy
betweenNRG-GFP and anAlexa 546-labeled antibody that rec-
ognized ErbB3 (Fig. 6C). In addition, energy transfer between
NRG-GFP and an Alexa 546-labeled anti-pErbB2 antibody
could also be detected (Fig. 6D). Incorporation of the metallo-
protease inhibitor TAPI-2 to prevent cleavage of membrane-
bound pro-NRG did not substantially affect these data, indicat-
ing that no major processing of NRG-GFP was taking place
along these experiments. Importantly, no energy transfer was
observed when the same experiments were carried out analyz-
ing NRG-GFP at the Golgi cisternae, indicating that although
pro-NRG and the receptors are expected to travel through the
same intracellular compartments while en route to the mem-
FIGURE 5. Cell surface pro-NRG2c activates signaling through ErbB receptors and is sensitive to trastuzumab. A, MCF7tetoff-NRG2c, MCF7tetoff-
NRGintra, and MCF7tetoff-NRG3-like cells were plated and treated with or without trastuzumab (50 nM). MTT metabolization was measured 3 days later. Results
are presented as the mean  S.D. (error bars) of quadruplicates of an experiment that was repeated twice. B, MCF7tetoff-NRG2c, MCF7tetoff-NRGintra, and
MCF7tetoff-NRG3-like cells cultured in the presence or absence of doxycycline (10 ng/ml) and treated with or without NRG (10 nM) for 15 min were lysed.
Immunoprecipitation (IP) (where pertinent) and Western blot (W) were performed with the indicated antibodies. C, pulse-chase analyses of pro-NRG2c and
pro-NRGintra. Cells were labeled with 200 Ci/ml of a mixture of [35S]cysteine and [35S]methionine for 20 min, and then the medium was replaced by fresh
complete medium. Cells were lysed at the indicated times. The extracts were immunoprecipitated with the anti-endodomain (for pro-NRG2c) or anti-NRG (for
pro-NRGintra) antibodies and analyzed in 8 or 10% SDS-polyacrylamide gels, followed by autoradiography. D, the graphic shows the percentage of intensity
of the sum of the bands of pro-NRG2c or pro-NRGintra with respect to the maximum value. E, MCF7tetoff-NRG2c or MCF7tetoff-NRGintra cells, cultured in the
presence of doxycycline (10 ng/ml) for the times indicated, and lysates were analyzed for expression of pro-NRG2c and pro-NRGintra by Western blotting with
the anti-endodomain or anti-NRG antibodies, respectively. F, the graphic shows the percentage of intensity of the sum of the bands of pro-NRG2c or
pro-NRGintra with respect to the maximum value.
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brane, the productive ligand-receptor interaction occurs only
at the plasma membrane.
Further evidence to support this latter conclusion was
searched by biochemical analyses of ErbB receptor activation in
cells forced to retain ErbB receptors and pro-NRG2c in intra-
cellular compartments in MCF7 cells. For these experiments,
we used brefeldin A, which prevents sorting of proteins from
the ER andGolgi to the plasmamembrane (35). Treatmentwith
this compound caused a clear redistribution of both pro-
NRG2c andErbB2 from the plasmamembrane to intracellular
vesicles that surrounded the nuclear compartment (Fig. 7A). As
reported previously (17, 18), treatment with brefeldin A
affected the electrophoretic mobility of the wild type pro-
NRG2c because, by interfering with the passage of pro-
NRG2c through intracellular membranes, it affects the matu-
ration of the pro-NRG2c oligosaccharide chains (Fig. 7B).
This treatment also affected the pattern of the pro-NRGintra.
Brefeldin A treatment strongly decreased pErbB2 and pErbB3
levels in MCF7-NRG2c cells when compared with untreated
cells (Fig. 7C). Moreover, intracellular retention of ErbB2 did
not favor its activation in MCF7-NRGintra cells. This conclu-
sion was further investigated by FRET analyses of the interac-
tion between NRG and ErbB3 or ErbB2 in cells treated with
brefeldin A, which was used to force entrapment of NRG,
ErbB3, and ErbB2 in intracellular compartments. Given the
precedent that treatment with brefeldin A resulted in loss of
pErbB2 (Fig. 7C), the potential existence of pro-NRG2c-
ErbB2 interactions was analyzed using anti-ErbB2 instead of
anti-pErbB2 antibodies. These experiments confirmed the lack
of interaction between pro-NRG and ErbB3 or ErbB2 (Fig. 7,D
and E, respectively) in the intracellular compartments even
when colocalization between the pro-NRG and the ErbB recep-
tors was forced by brefeldin A. Together, these data indicate
that intracellular pro-NRG2c is unable to interact with the
ErbB receptors, at least in a productive manner. However, the
FRET experiments indicated that pro-NRG could act on self
receptors (in cis) but only when both the transmembrane fac-
tors and the receptors are exposed at the cell surface.
DISCUSSION
A unique structural property of most type I transmembrane
pro-NRGs is their absence of an N-terminal signal sequence.
This characteristic raises the question of what regions of these
pro-NRGs are required for their membrane anchoring and tar-
geting to the plasma membrane. Previous reports suggested
that the internal hydrophobic region could act as a signal
sequence due to the failure to detect NRG3, which lacks this
region, in the extracellular medium (15). The studies presented
here with the different pro-NRG2c mutants indicate that in
fact, the internal hydrophobic region of pro-NRG2c may act
as an internal signal sequence. Moreover, we report that this
region is responsible for the membrane-anchoring properties
of type I transmembrane NRGs. In fact, elimination of the
extracellular or intracellular domains of pro-NRG2c preserv-
ing this internal hydrophobic region resulted in mutant forms
that associated with microsomal membranes. Interestingly,
FIGURE 6. pro-NRG2c may act in cis at the plasma membrane. A, schematic representation of FRET experiments. NRG-GFP was excited with the argon
470-nm laser line. If the intracellular domain of ErbB receptors is close enough, energy is transferred to Alexa 546 anti-pErbB2 or anti-ErbB3 antibodies can be
detected at 573 nm. B, expression of NRG-GFP at the plasma membrane. Shown is FRET energy transfer between NRG-GFP and Alexa 546-conjugated ErbB3 (C)
or Alexa 546-conjugated pErbB2 (D). Where indicated, TAPI-2 (TAPI; 10 M) was added to the culture medium. FRET measurements were made at the plasma
membrane or at the Golgi complex. The results shown are the mean  S.D. (error bars) of three independent experiments.
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some of thesemutants failed to reach the plasmamembrane, as
indicated by the protease protection experiments, the cytom-
etry, or the immunofluorescent stainings. Thus, deletion of the
intracellular domain of pro-NRG2c created a mutant form of
the protein that retained membrane anchoring capability but
was unable to reach the plasma membrane. This finding sug-
gests that the internal hydrophobic region of pro-NRG2c con-
fers membrane-anchoring properties but is not sufficient to
provide cell surface targeting properties. It also indicates that
the intracellular domain of pro-NRG2c is required for its ade-
quate sorting to the plasma membrane. Importantly, the C ter-
minus of pro-NRG2c includes a valine residue that could play
a role in directing pro-NRG2c to the plasma membrane, in
analogy to the critical role that C-terminal intracellular valines
play in the adequate sorting of the related EGF family member
pro-TGF (36, 37).
Deletionof the extracellulardomainofpro-NRG2c resulted in
amutant protein that associatedwith themicrosomal fraction and
apparentlywas correctly targeted to the cell surface.This indicates
that the extracellular regionofpro-NRG2c isnot required for the
sorting to the plasmamembrane and suggests that the transmem-
brane and intracellular regions of pro-NRG2c may be sufficient
to confermembrane-anchoring and cell surface-targeting proper-
ties to pro-NRGs but not to any protein. In fact, the chimeric
ERK5-NRG proteins showed targeting of these chimeric proteins
to microsomes, further confirming that the internal hydrophobic
region conferred membrane-anchoring properties. However,
these chimeras failed to reach the cell surface, indicating that the
transmembrane and intracellular regions do not have sufficient
strength to move any sequence to the plasma membrane and
therefore require a permissive extracellular sequence tomove the
protein to that location.
FIGURE 7. Intracellular pro-NRG2c fails to activate ErbB receptors. A, subcellular distribution of pro-NRG2c and ErbB2 in MCF7 cells treated with brefeldin
A. MCF7 cells were cultured on coverslips and 1 day later were treated with or without brefeldin A (10 g/ml) overnight. B, effect of brefeldin A on pro-NRG2c
and the pro-NRGintra mutant. The extracts were immunoprecipitated and analyzed by Western blot with the anti-ectodomain antibodies. C, MCF7, MCF7-
NRG2c, and MCF7-NRGintra cells treated with brefeldin A overnight were lysed. The extracts were immunoprecipitated (IP) with the anti-ErbB2 or anti-ErbB3
antibodies, and Western blot (WB) was performed with the anti-phosphotyrosine (-pTyr) antibody. Shown are FRET analyses of the interactions between NRG
and ErbB3 (D) and between NRG and ErbB2 (E). Where indicated, brefeldin A (10 g/ml) was added to the culture medium overnight. FRET measurements were
made at the plasma membrane or in intracellular compartments (GA/ER). The results shown are the mean  S.D. (error bars) of three independent experiments.
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Accumulation of pro-NRGintra in intracellular microsomal
compartments offered the possibility to explore whether at
such a location this pro-NRG form was active. This was an
important aspect of our research because former studies car-
ried out with mutant forms of pro-EGF indicated that intracel-
lular entrapment of EGF was able to activate the EGF receptor
in an intracrine manner (25–27). Expression of pro-NRGintra
inMCF7 cells was unable to activate NRG receptors, indicating
that intracellular NRG is unable to activate the ErbB receptors.
The failure to activate ErbB receptors at this intracellular loca-
tion is unknown. Because pro-NRGs and the ErbB receptors are
transmembrane proteins that move to the cell surface, they are
expected to share the export machinery, and it is therefore
likely that they coincide with each other along the secretory
pathway responsible for their targeting to the plasma mem-
brane. In MCF7 cells, ErbB2 and ErbB3, although traveling
through the same compartments as pro-NRG, are not easily
detected in these intracellular sites by regular immunofluores-
cence techniques, indicating that their export to the surface is
efficient, probably more than that of pro-NRG, which may be
detected at the Golgi cisternae. The rapid movement to the
membrane may therefore restrict the time that the ErbB recep-
tors reside in intracellular sorting compartments, diminishing
access to pro-NRG, and this could explain the lack of activation
of ErbB receptors in cells expressing pro-NRGintra. We
attempted to force such an intracellular interactionwith brefel-
din A. Treatment with this compound failed to increase ErbB2
and ErbB3 phosphorylation in cells expressing pro-NRGintra.
Moreover, this drug caused inhibition of ErbB2 and ErbB3
tyrosine phosphorylation in cells expressing wild type pro-
NRG2c. In addition, FRET experiments failed to detect inter-
action between pro-NRG2c and its receptors in intracellular
compartments, even under conditions, such as brefeldin A
treatment, that force retention of the ligand and the receptors
probably in the same intracellular compartments. These results
indicate that in intracellular compartments, transmembrane
NRG is signaling-incompetent. Such a failure to activate ErbB
receptors may be caused by segregation of the receptor and the
ligands in these intracellular compartments or by deficient pro-
NRG-ErbB interaction due to intrinsic characteristics of these
compartments, such as low lumenal pH. Another possibility
thatmay explain the failure of intracellular pro-NRG to activate
ErbB receptors is incomplete maturation of the membrane-
bound factor at these intracellular sites. It is also possible that
the failure of the pro-NRGintra to stimulate MCF7 prolifera-
tion could be due to instability of this protein with respect to
wild type pro-NRG2c. The half-lives of both proteins were
found to be similar, as indicated by the pulse-chase radioactive
experiments as well as results obtained in the doxycycline-reg-
ulatable cell models. It is therefore unlikely that different sta-
bilities of both proteins may explain their distinct biological
properties.
From the physiological point of view, our results help in
explaining the failure of pro-NRGmutants with deletion in the
intracellular domain to carry out their function during devel-
opment (38, 39). Liu et al. (38, 39) reported a role of the NRG
tail in animal development because mice expressing a pro-
NRGintra-like form presented a phenotype analogous to NRG
null mice. The authors suggested that this form was unable to
dimerize, and this could result in its deficient cleavage and sol-
ubilization. Our results suggest that deficient release of soluble
NRG in pro-NRGintra-expressing cells is due to lack of cell
surface exposure; the site where the protease that cleaves the
ectodomain of pro-NRGs is active (17, 18).
Another question that we addressedwaswhether transmem-
brane ligands can activate their receptors in cis. Previous stud-
ies have already demonstrated that pro-NRGs may activate
ErbB receptors in a juxtacrine manner (in trans) (9, 17, 24). In
isolated MCF7 cells expressing pro-NRG2c, FRET measure-
ments showed interaction of ErbB3 and pErbB2 with pro-
NRG2c but only when the factor and the receptor were pres-
ent at the plasma membrane. This indicates that pro-NRG2c
may activate ErbB receptors located in the same cell that pro-
duces the ligand, in addition to acting on receptors located in
cells that are in physical contactwith the growth factor-produc-
ing cell. We term this transautocrine stimulation, to indicate
this binary potential of action of a transmembrane growth fac-
tor on receptors. Although the soluble crystals of NRGwith the
ectodomain of their receptors have been solved (40), these
structures cannot answer at present how a transmembrane fac-
tor may interact with ErbB receptors in a transautocrine man-
ner. It appears likely that both the membrane factor and the
receptor must have a substantial degree of flexibility to be able
to interact at the plasmamembrane, especially considering that
the ligand binding regions are shared between subdomains I
and III of the receptors.We are expecting structural studies that
will define how a membrane-anchored pro-NRG may interact
with its receptors.
In conclusion, our work has established that the internal
hydrophobic region of type I transmembrane NRGs is compe-
tent to act as a membrane-anchoring and signal sequence
domain. Our findings also allowed dissection between mem-
brane-anchoring and cell surface-targeting properties of these
pro-NRGs. In addition, we offer for the first time evidence indi-
cating that transmembrane growth factors may activate their
receptors in cis. These findings contribute to a better under-
standing of the biological properties of membrane-anchored
growth factors that may be useful in the design of therapeutic
strategies for diseases involving transmembrane NRGs.
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